The article focuses on Amgen's acquisition of Micromet on March 7, 2012. The purchase reportedly puts Amgen's hand into a cancer immunotherapy based on the bispecific monoclonal antibody (mAb) fragment blinatumomab and T cell receptor as well as the bispecific T cell engager (BiTE) that gave rise to it. Several other companies have also BiTE-based drug development collaborations with Micromet including Sanofi and Boehringer Ingelheim.